Aeterna Zentaris, Sinopharm Sign Collaboration Agreement For Cancer Drug

(RTTNews) - Aeterna Zentaris Inc. (AEZS) Monday said it signed a license and technology transfer agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for its cancer drug, for China, Hong Kong and Macau.

Zoptarelin doxorubicin is in a Phase 3 trial for endometrial cancer in women, as well as a Phase 2 trial for prostate cancer.

Aeterna Zentaris will be paid a non-refundable $1 million fee for transfer of the technology, with further payments based on the achievement of certain pre-established regulatory and commercial milestones, the company said. Aeterna Zentaris will also receive royalties on future sales of the drug in the above mentioned markets.